1614 related articles for article (PubMed ID: 27353420)
41. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Blotner S; Chen LC; Ferlini C; Zhi J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
[TBL] [Abstract][Full Text] [Related]
42. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
43. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
44. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
Carter BZ; Mak PY; Tao W; Zhang Q; Ruvolo V; Kuruvilla VM; Wang X; Mak DH; Battula VL; Konopleva M; Jabbour EJ; Hughes PE; Chen X; Morrow PK; Andreeff M
Mol Cancer Ther; 2022 Jun; 21(6):879-889. PubMed ID: 35364607
[TBL] [Abstract][Full Text] [Related]
45. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
46. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
[TBL] [Abstract][Full Text] [Related]
48. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
[TBL] [Abstract][Full Text] [Related]
49. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
51. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
52. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
[TBL] [Abstract][Full Text] [Related]
53. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
[TBL] [Abstract][Full Text] [Related]
55. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
56. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
57. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
58. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Corbali MO; Eskazan AE
Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
[No Abstract] [Full Text] [Related]
59. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
60. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]